• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.28
  • VXN 19.85
  • VXO 16.61
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Last Trade Dividend/Share PE Ratio
Date Dividend Yield Return on Assets
Change ExDividend Date Return on Capital
Bid Latest EPS Price/Sale
Ask LatestEPS Date Price to Book
Volume EPS ttm Institutional %
Avg Volume Shares Outstanding Insider %
Open Float Short Ratio
Prev Close Return On Equity 5 Year Change %
High Consensus EPS 2 Year Change %
Low No. of Estimate 1 Year Change %
52 Week High EPS Surprise $ YTD Change %
52 Week Low EPS Surprise Percent 6 Month Change %
52 Week Change EBITDA 3 Month Change %
50 Day MA Revenue 1 Month Change %
200 Day MA Gross Profit 5 Day Change %
Market Cap Cash 30 Day Change %
Beta Debt Stock Exchange
Sector Revenue Per Share Short Interest
Short Date Revenue Per Employee Short Ratio
Data courtesy of IEX
Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate, AFREZZA, a rapid-acting insulin that has completed Phase III clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company is also preparing to initiate a Phase II study of MKC1106-MT in patients with advanced melanoma. Its products also include MKC253 (GLP-1), a Phase I clinical trials product for the treatment of type 2 diabetes; and MKC1106-PP, a Phase I clinical trials product for the treatment of diverse tumor types, metastatic diseases, and/or progressive, refractory disease. In addition, the company conducts preclinical studies of drug candidates, MKC204, which may have the potential to treat certain malignancies and inflammatory diseases; MKC180, an obesity compound; and MKC1106-NS, a cancer immunotherapy product. MannKind Corporation was founded in 1991 and is based in Valencia, California.